<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692107</url>
  </required_header>
  <id_info>
    <org_study_id>CKVO 96-10</org_study_id>
    <nct_id>NCT00692107</nct_id>
  </id_info>
  <brief_title>Radiotherapy for Prostate Cancer: Conventional Dose Versus High Dose</brief_title>
  <official_title>Phase III Study for Prostate Cancer, Randomizing Between Two Radiation Dose Levels (68 Gy vs. 78 Gy) and Utilizing Three Dimensional Conformal Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      3-D conformal radiotherapy offers the opportunity to reach higher tumor doses with acceptable
      complication rates compared to conventional radiotherapy. There are retrospective and
      preliminary prospective reports of a better local control / disease free survival (including
      PSA control) using higher tumor doses. A prospective randomised phase III study is required
      to validate these reports. The purpose of this randomized phase III study is to investigate
      and compare the tumor control and toxicity in prostate cancer patients treated to 68 Gy and
      78 Gy;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were stratified by hospital, treatment group, age and (neo)adjuvant hormonal
      therapy. Four treatment groups with specific radiation volumes were defined depending on the
      estimated risk of tumour involvement of the seminal vesicles (based on T-stage, initial PSA
      and Gleason Score or Differentiation Grade).The dose was delivered with daily fractions of 2
      Gy, five times a week. The total duration of the treatment was 7 weeks for patients treated
      to 68 Gy and 8 week for 78 Gy.

      Objectives:

        -  To test in a phase III randomised study the hypothesis that higher radiation doses lead
           to a higher freedom from failure rate for localized prostate cancer.

        -  To test the hypothesis that a higher freedom from failure rate leads to a longer
           disease-free survival and overall survival.

        -  To limit acute and late toxicity with respect to gastro-intestinal and urological
           toxicity.

        -  To evaluate different PSA related endpoints for local failure and distant metastasis.

        -  To establish a database of patients treated to escalated doses with Dose Volume
           Histograms of the normal tissues at risk for each individual patient and common toxicity
           endpoints.

        -  To validate a model to estimate normal tissue complication probabilities (NTCPs) of
           rectum and bladder, based on the above-mentioned database, and to obtain reliable
           parameter values for NTCP estimations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from failure</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from clinical failure</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">669</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>68 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>78 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gray</intervention_name>
    <description>68 Gy vs. 78 Gy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gray</intervention_name>
    <description>68 Gy vs. 78 Gy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  locally confined adenocarcinoma of the prostate

          -  all T-stages with a PSA &lt; 60ng/ml, except any T1a tumor and well-differentiated (or
             Gleason score &lt; 5) T1b-c tumors with PSA-levels â‰¤ 4 ng/ml

          -  Karnofsky Performance Status of 80 or more

        Exclusion Criteria:

          -  distant metastases

          -  positive regional lymph nodes proven by surgical or cytological sampling

          -  on anticoagulants

          -  previous prostatectomy

          -  previous pelvic irradiation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joos V Lebesque, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiotherapeutic Institute Friesland</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeeuws Radiotherapeutic Institute</name>
      <address>
        <city>Vlissingen</city>
        <zip>4382 EE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1019-34.</citation>
    <PMID>15752881</PMID>
  </results_reference>
  <results_reference>
    <citation>Peeters ST, Hoogeman MS, Heemsbergen WD, Slot A, Tabak H, Koper PC, Lebesque JV. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1142-52. Epub 2005 Jun 4.</citation>
    <PMID>15939547</PMID>
  </results_reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>June 5, 2008</last_update_submitted>
  <last_update_submitted_qc>June 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. J. Lebesque, Dr. P. Koper</name_title>
    <organization>Erasmus Medical Center / The Netherlands Cancer Institute</organization>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

